SCHEMBL10143964

SCHEMBL10143964

Brc1ccc(/C=N/Nc2ccc3ccccc3n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 1.00
MAPT P10636 11/20 1.00
NPC1 O15118 11/20 1.00
KMT2A Q03164 10/20 1.00
SMN1; SMN2 Q16637 10/20 1.00
KDM4E B2RXH2 7/20 1.00
MEN1 O00255 7/20 1.00
HTT P42858 6/20 0.66
TP53 P04637 2/20 0.66
NFKB1 P19838 1/20 0.66
NFKB2 Q00653 1/20 0.66
RELA Q04206 1/20 0.66
GAA P10253 6/20 0.61
LMNA P02545 4/20 0.61
POLB P06746 1/20 0.61
XBP1 P17861 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
ALDH1A1 P00352 4/20 0.60
MAPK1 P28482 2/20 0.60
TDP1 Q9NUW8 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29033679 0.88 KMT2A (0.78) RAB9AMAPTNPC1KMT2ASMN1; SMN2
SCHEMBL17190844 0.88 KMT2A (0.78) RAB9AMAPTNPC1KMT2ASMN1; SMN2
SCHEMBL19535031 0.79 KMT2A (0.64) RAB9AMAPTNPC1KMT2ASMN1; SMN2
SCHEMBL19535032 0.79 KMT2A (0.64) RAB9AMAPTNPC1KMT2ASMN1; SMN2
SCHEMBL19321533 0.78 MAPT (0.64) RAB9AMAPTNPC1KMT2ASMN1; SMN2
SCHEMBL4929465 0.78 PAX8 (0.73) RAB9AMAPTNPC1KMT2ASMN1; SMN2
SCHEMBL10144051 0.75 MAPT (1.00) RAB9AMAPTNPC1KMT2ASMN1; SMN2
SCHEMBL1164645 0.73 PAX8 (1.00) RAB9AMAPTNPC1KMT2ASMN1; SMN2
SCHEMBL1164644 0.73 PAX8 (1.00) RAB9AMAPTNPC1KMT2ASMN1; SMN2
SCHEMBL29692738 0.73 PAX8 (1.00) RAB9AMAPTNPC1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS BIOMARIN PHARMACEUTICAL INC. 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS ENGASE, GALNT1, GALNT13 RAB9A 3256/4885MAPT 2982/4885NPC1 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.